Does Mounjaro always work, and what does the evidence say?

What the trial data actually found at different dose levels

The SURMOUNT-1 trial (published in the New England Journal of Medicine and involving 2,539 adults with obesity) remains the clearest picture we have of how tirzepatide performs across a range of doses. Average body-weight reductions were around 15% at 5mg, around 19.5% at 10mg, and approximately 20–21% at 15mg over 72 weeks, all in participants who also made dietary changes.

Those are averages. Within each dose group there were people who lost considerably more and people who lost less. The proportion who reached a 20% or greater reduction grew sharply with dose — from roughly a quarter at 5mg to well over half at 15mg. Reaching the highest tolerated dose, and staying on it, matters a great deal to the outcome.

If you're curious about the biology behind these results, our page on how Mounjaro works helps explain some of this variation. It activates two gut-hormone receptors simultaneously, slowing gastric emptying and reducing appetite signals in a way that is genuinely novel, and if you want to go deeper on the mechanism, our guide on how tirzepatide works at a biochemical level is a useful place to start. But receptor sensitivity differs between people, and that partly explains why identical doses produce different results.

Factors that reduce how well Mounjaro works in practice

Non-response to tirzepatide is rarely a single cause. A few patterns come up repeatedly in clinical practice. First, titration pace. The first pen's job is to help your body adjust; the dose that drives weight loss comes later in the schedule. People who stop early (often because of manageable nausea that would have settled) miss most of the effect.

Second, consistency. Mounjaro is a once-weekly injection, and timing matters. Missing doses or injecting significantly late disrupts the steady blood-level profile the medicine relies on. Third, lifestyle context. The trial participants followed a reduced-calorie diet alongside treatment; the medicine reduces appetite but does not eliminate the need for some conscious effort around food and activity.

Underlying health conditions can also influence response. Certain thyroid disorders, for instance, interact with metabolic rate in ways that affect weight, if this is something you're curious about, Mounjaro and Hashimoto's disease is worth reading. Medicines taken alongside tirzepatide occasionally affect its absorption or its effect on blood sugar.

One side effect worth knowing about: some people report feeling colder than usual during treatment, which appears to relate to changes in metabolic activity. If you've noticed this yourself, our page on why you might feel always cold on Mounjaro discusses the reasons behind it in more detail.

What NICE says about reviewing progress, and what it means for you

NICE's appraisal of tirzepatide (TA1026) includes a specific checkpoint: if someone has not lost at least 5% of their starting body weight after six months at the highest dose they can tolerate, continuing treatment should be reviewed. That threshold exists because, in people who do not respond at all by six months, continued treatment is unlikely to produce a different outcome.

What TA1026 does not say is that slow early progress means failure. The titration period is gradual by design, and meaningful loss during it is not the primary goal. The clinical question is how things look once you have been on a stable, effective dose for long enough to judge.

If you want to explore what the cost of private treatment looks like and what is included in a single transparent price, the weight-loss treatments page lays that out. Cost is a real consideration; it is worth understanding before starting so that the titration period does not get cut short for financial reasons.

What to do if Mounjaro is not working as expected

The first conversation is with your prescriber, not a forum. They can assess whether the dose is right, whether something is affecting absorption, whether an underlying condition needs attention, and whether the timeline is realistic given where you are in the titration schedule. That review should happen before any decision to stop or switch.

At nume, every repeat order goes back to a clinician before it is issued, a real prescriber reads your progress notes, not software. If something is not going as expected, that review is the moment to say so. You can also reach our aftercare team between orders, seven days a week.

Mounjaro is not a certainty. No prescription medicine is. But its trial results are among the strongest seen in weight management, and most people who reach an effective dose and stay on it do lose clinically significant weight. The question worth asking (with a prescriber, based on your own health picture) is whether it is the right option for you. If you would like to find out, you can speak to our prescribers through a free consultation today.